MA30290B1 - Therapie antitumorale a l'aide d'un anticorps contre le facteur de croissance endotheliale vasculaire et d'un anticorps contre le recepteur du facteur de croissance epitheliale humain de type 2 - Google Patents

Therapie antitumorale a l'aide d'un anticorps contre le facteur de croissance endotheliale vasculaire et d'un anticorps contre le recepteur du facteur de croissance epitheliale humain de type 2

Info

Publication number
MA30290B1
MA30290B1 MA31255A MA31255A MA30290B1 MA 30290 B1 MA30290 B1 MA 30290B1 MA 31255 A MA31255 A MA 31255A MA 31255 A MA31255 A MA 31255A MA 30290 B1 MA30290 B1 MA 30290B1
Authority
MA
Morocco
Prior art keywords
growth factor
antibody against
vascular endothelial
tumor therapy
factor receptor
Prior art date
Application number
MA31255A
Other languages
English (en)
Inventor
Thomas Friess
Max Hasmann
Werner Scheuer
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37998279&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA30290(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA30290B1 publication Critical patent/MA30290B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention propose un procédé de traitement d'un cancer du sein chez un patient pour lequel un traitement précédent avec un anticorps anti-VEGF a échoué, comprenant l'administration audit patient d'une quantité thérapeutiquement efficace d'un anticorps anti-HER2 tout en poursuivant ledit traitement par l'anticorps anti-VEGF. L'invention propose également des articles de fabrication et des compositions pharmaceutiques correspondants.
MA31255A 2006-03-22 2008-09-22 Therapie antitumorale a l'aide d'un anticorps contre le facteur de croissance endotheliale vasculaire et d'un anticorps contre le recepteur du facteur de croissance epitheliale humain de type 2 MA30290B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06111523 2006-03-22
EP06021815 2006-10-18

Publications (1)

Publication Number Publication Date
MA30290B1 true MA30290B1 (fr) 2009-03-02

Family

ID=37998279

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31255A MA30290B1 (fr) 2006-03-22 2008-09-22 Therapie antitumorale a l'aide d'un anticorps contre le facteur de croissance endotheliale vasculaire et d'un anticorps contre le recepteur du facteur de croissance epitheliale humain de type 2

Country Status (24)

Country Link
US (4) US20070224203A1 (fr)
EP (2) EP2364732B1 (fr)
JP (2) JP5795463B2 (fr)
KR (1) KR101089070B1 (fr)
AR (1) AR059982A1 (fr)
BR (1) BRPI0709025A2 (fr)
CA (1) CA2645891A1 (fr)
CR (1) CR10244A (fr)
DK (2) DK2364732T3 (fr)
EC (1) ECSP088753A (fr)
ES (2) ES2392873T3 (fr)
HU (1) HUE029615T2 (fr)
IL (1) IL193675A0 (fr)
MA (1) MA30290B1 (fr)
MX (1) MX2008012014A (fr)
MY (1) MY151449A (fr)
NO (1) NO20083761L (fr)
NZ (1) NZ570921A (fr)
PL (2) PL2364732T3 (fr)
RU (1) RU2538664C2 (fr)
SG (1) SG170730A1 (fr)
SI (2) SI1998805T1 (fr)
TW (1) TW200812615A (fr)
WO (1) WO2007107329A1 (fr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA9811162B (en) * 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
WO2001089566A1 (fr) 2000-05-19 2001-11-29 Genentech, Inc. Analyse de detection genique permettant d'ameliorer la probabilite d'une reponse efficace a une therapie du cancer basee sur un antagoniste d'erbb
RS20150135A1 (sr) 2003-05-30 2015-08-31 Genentech Inc. Tretman sa anti-vegf antitelima
UA90480C2 (uk) * 2004-07-22 2010-05-11 Джэнэнтэк, Инк. Фармацевтична композиція, що має протипухлинну активність, яка включає антитіло до her2
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
CA2587519A1 (fr) * 2004-12-07 2006-06-15 Genentech, Inc. Selection de patients pour une therapie avec un inhibiteur de her
EP3698807A1 (fr) 2005-01-21 2020-08-26 Genentech, Inc. Dosage fixe d'anticorps anti-her
RS53128B (sr) 2005-02-23 2014-06-30 Genentech Inc. Produžavanje vremena progresije bolesti ili preživljavanja kod pacijenata obolelih od kancera jajnika korišćenjem pertuzumaba
PE20070207A1 (es) * 2005-07-22 2007-03-09 Genentech Inc Tratamiento combinado de los tumores que expresan el her
TW200812615A (en) 2006-03-22 2008-03-16 Hoffmann La Roche Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
AU2007287794B2 (en) * 2006-08-21 2013-03-28 F. Hoffmann-La Roche Ag Tumor therapy with an anti-VEGF antibody
MX2009008981A (es) 2007-03-02 2009-09-02 Genentech Inc Prediccion de respuesta a un inhibidor her.
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
US8268314B2 (en) 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
WO2012169822A2 (fr) * 2011-06-10 2012-12-13 강원대학교산학협력단 Protéine de fusion permettant de supprimer la croissance des cellules cancéreuses et la vasculogenèse et composition anticancéreuse la contenant
KR101397088B1 (ko) 2011-06-10 2014-05-19 강원대학교산학협력단 암세포 증식 억제와 혈관신생 억제를 위한 융합 단백질 및 이를 포함한 항암 조성물
HUE044352T2 (hu) 2011-10-14 2019-10-28 Hoffmann La Roche Pertuzumab, Trastuzumab, Docetaxel és Carboplatin korai stádiumú mellrák kezelésére
SI3495387T1 (sl) 2012-07-13 2021-12-31 Roche Glycart Ag Bispecifična protitelesa proti VEGF/proti ANG-2 in njihova uporaba pri zdravljenju bolezni očesnih žil
MX365567B (es) 2013-03-13 2019-06-07 Genentech Inc Formulaciones de anticuerpo.
MY173295A (en) 2013-04-16 2020-01-14 Genentech Inc Pertuzumab variants and evaluation thereof
BR112016024789A2 (pt) 2014-04-25 2017-10-24 Genentech Inc métodos de tratamento de câncer de mama em fase inicial com trastuzumabe-mcc-dm1 e pertuzumabe
ES2949173T3 (es) 2014-09-15 2023-09-26 Hoffmann La Roche Formulaciones de anticuerpo
JP6822980B2 (ja) 2015-05-30 2021-01-27 ジェネンテック， インコーポレイテッド Ｈｅｒ２陽性転移性乳癌の治療方法
WO2017087280A1 (fr) 2015-11-16 2017-05-26 Genentech, Inc. Procédés de traitement d'un cancer positif her2
CN106729743B (zh) * 2015-11-23 2021-09-21 四川科伦博泰生物医药股份有限公司 抗ErbB2抗体-药物偶联物及其组合物、制备方法和应用
JP6914336B2 (ja) 2016-12-28 2021-08-04 ジェネンテック， インコーポレイテッド 進行したｈｅｒ２発現がんの治療
DK3570884T3 (da) 2017-01-17 2020-11-30 Genentech Inc Subkutane HER2-antistofformuleringer
HUE064898T2 (hu) 2017-03-02 2024-04-28 Genentech Inc HER2-pozitív emlõrák adjuváns kezelése
WO2018200505A1 (fr) 2017-04-24 2018-11-01 Genentech, Inc. Mutations erbb2/her2 dans le domaine transmembranaire ou juxtamembranaire
CN111699004A (zh) 2018-02-06 2020-09-22 豪夫迈·罗氏有限公司 眼科疾病的治疗
CN119033684A (zh) 2018-10-29 2024-11-29 豪夫迈·罗氏有限公司 抗体制剂
JP2023532122A (ja) 2020-06-29 2023-07-26 ジェネンテック， インコーポレイテッド ペルツズマブにトラスツズマブを加えた固定用量配合剤

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989006692A1 (fr) 1988-01-12 1989-07-27 Genentech, Inc. Procede de traitement de cellules tumorales par inhibition de la fonction receptrice du facteur de croissance
US5834229A (en) 1991-05-24 1998-11-10 Genentech, Inc. Nucleic acids vectors and host cells encoding and expressing heregulin 2-α
WO1994004679A1 (fr) 1991-06-14 1994-03-03 Genentech, Inc. Procede pour fabriquer des anticorps humanises
EP0590058B1 (fr) 1991-06-14 2003-11-26 Genentech, Inc. ANTICORP HUMANISE specifique pour heregulin
KR100335584B1 (ko) 1992-10-28 2002-11-29 제넨테크, 인코포레이티드 혈관내피세포성장인자에대한길항제
BR9709974A (pt) 1996-06-27 1999-08-10 Pfizer Derivados de 2-(2-oxo-etidileno)-imidazolidin-4-ona e seu uso como inibidores da transferase da proteina de farnesila
CN101412758A (zh) 1996-10-18 2009-04-22 基因技术股份有限公司 抗ErbB2抗体
US6884879B1 (en) * 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
DE69829891T2 (de) * 1997-04-07 2005-10-06 Genentech, Inc., South San Francisco Anti-VEGF Antikörper
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
CN104231078A (zh) 1997-04-07 2014-12-24 基因技术股份有限公司 抗-血管内皮生长因子的抗体
ZA9811162B (en) 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
JPH11236333A (ja) 1997-12-30 1999-08-31 Pfizer Prod Inc 抗ガン剤として有用なイミダゾリン−４−オン誘導体
AU4079999A (en) 1998-05-15 1999-12-06 Imclone Systems Incorporated Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases
CA2341739C (fr) 1998-08-27 2005-07-12 Pfizer Products Inc. Derives de quinolin-2-one utiles en tant qu'agents anticancereux
KR20010072991A (ko) 1998-08-27 2001-07-31 실버스타인 아써 에이. 항암제로서 유용한 알키닐-치환된 퀴놀린-2-온 유도체
AU1728800A (en) 1998-11-18 2000-06-05 Genentech Inc. Antibody variants with higher binding affinity compared to parent antibodies
EP1006113A1 (fr) 1998-12-02 2000-06-07 Pfizer Products Inc. Dérivés de 2-(2-oxo-éthylidène)-imidazolidin-4-one et leur utilisation pour inhiber la croissance anormale des cellules
WO2000035956A1 (fr) 1998-12-16 2000-06-22 Kyowa Hakko Kogyo Co., Ltd. Anticorps monoclonal anti-vegf humain
EP1579871A1 (fr) * 1998-12-22 2005-09-28 Genentech, Inc. Antagonistes du facteur de croissance endotheliale et leurs utilisations
TR200201296T2 (tr) 1999-02-11 2002-07-22 Pfizer Products Inc. Antikanser maddeleri olarak faydalı heteroaril-ikame edilmiş kinolin-2-on türevleri
PT1157041E (pt) 1999-03-01 2005-10-31 Genentech Inc Anticorpos para terapia e diagnostico de cancro
US6586447B1 (en) 1999-04-01 2003-07-01 Pfizer Inc 3,3-disubstituted-oxindole derivatives useful as anticancer agents
EP1179541B1 (fr) * 1999-04-28 2004-06-16 Board Of Regents, The University Of Texas System Compositions et procédes de traitment du cancer par l'inhibition sélective du VEGF
SI1187632T1 (sl) 1999-05-14 2009-04-30 Genentech Inc Zdravljenje z anti-ErbB2 protitelesi
DE60033658T2 (de) 1999-06-25 2007-11-22 Genentech, Inc., South San Francisco Behandlung von prostata-krebs mit anti-erbb2 antikörpern
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
AR024464A1 (es) 1999-06-25 2002-10-02 Genentech Inc Anticuerpos anti-erbb2 humanizados.
WO2001029025A2 (fr) * 1999-10-19 2001-04-26 Merck & Co., Inc. Inhibiteurs de tyrosine kinases
ES2212971T3 (es) 1999-11-30 2004-08-16 Pfizer Products Inc. Derivados de quinolina utiles para la inhibicion de la farnesil protein transferasa.
UA75055C2 (uk) 1999-11-30 2006-03-15 Пфайзер Продактс Інк. Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі
HN2000000266A (es) 2000-01-21 2001-05-21 Pfizer Prod Inc Compuesto anticanceroso y metodo de separacion de enantiomeros util para sintetizar dicho compuesto.
US20060036086A1 (en) 2002-03-12 2006-02-16 Jain Rakesh K Use of signal transduction inhibitors and combination therapies for the prevention or treatment of cancer and angiogenesis related diseases
JP2005522514A (ja) 2002-04-10 2005-07-28 ジェネンテック・インコーポレーテッド 抗ｈｅｒ２抗体改変体
US20040243207A1 (en) 2003-05-30 2004-12-02 Olson Donald R. Medical implant systems
RS20150135A1 (sr) 2003-05-30 2015-08-31 Genentech Inc. Tretman sa anti-vegf antitelima
JP2007501011A (ja) 2003-08-01 2007-01-25 ジェネンテック・インコーポレーテッド 制限多様性配列を有する結合型ポリペプチド
AR046639A1 (es) 2003-11-21 2005-12-14 Schering Corp Combinaciones terapeuticas de anticuerpo anti- igfr1
PT1718677E (pt) 2003-12-19 2012-07-18 Genentech Inc Fragmentos de anticorpo monovalentes úteis como agentes terapêuticos
TW200812615A (en) * 2006-03-22 2008-03-16 Hoffmann La Roche Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2

Also Published As

Publication number Publication date
WO2007107329A1 (fr) 2007-09-27
JP5795463B2 (ja) 2015-10-14
EP1998805B1 (fr) 2012-08-22
CR10244A (es) 2008-10-29
BRPI0709025A2 (pt) 2011-06-21
EP2364732A1 (fr) 2011-09-14
AU2007229008A1 (en) 2007-09-27
TW200812615A (en) 2008-03-16
SG170730A1 (en) 2011-05-30
US9090700B2 (en) 2015-07-28
US20110064736A1 (en) 2011-03-17
PL1998805T3 (pl) 2013-01-31
HUE029615T2 (en) 2017-03-28
EP1998805A1 (fr) 2008-12-10
CA2645891A1 (fr) 2007-09-27
EP2364732B1 (fr) 2016-07-06
JP2009530333A (ja) 2009-08-27
US20070224203A1 (en) 2007-09-27
DK1998805T3 (da) 2012-10-08
NO20083761L (no) 2008-10-09
US20170239353A1 (en) 2017-08-24
KR20080096598A (ko) 2008-10-30
KR101089070B1 (ko) 2011-12-05
SI2364732T1 (sl) 2016-12-30
JP2012207036A (ja) 2012-10-25
RU2008141433A (ru) 2010-04-27
ECSP088753A (es) 2008-10-31
HK1131037A1 (en) 2010-01-15
PL2364732T3 (pl) 2017-01-31
ES2392873T3 (es) 2012-12-14
IL193675A0 (en) 2011-08-01
SI1998805T1 (sl) 2012-12-31
DK2364732T3 (en) 2016-10-10
US20150283238A1 (en) 2015-10-08
MY151449A (en) 2014-05-30
RU2538664C2 (ru) 2015-01-10
ES2595238T3 (es) 2016-12-28
MX2008012014A (es) 2008-10-01
AR059982A1 (es) 2008-05-14
NZ570921A (en) 2011-09-30

Similar Documents

Publication Publication Date Title
SG170730A1 (en) Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
NZ606825A (en) Methods and compositions for treating complement-associated disorders
NZ597830A (en) Methods and compositions for treating cancer comprising abiraterone acetate and prednisone
MA34172B1 (fr) Anticorps bispécifiques, bivalents anti-vegf/anti-ang-2
SG166093A1 (en) Inhibitors of brutonæs tyrosine kinase
EP1765362A4 (fr) Compositions et méthodes pour le traitement de maladies néovasculaires
RU2009148278A (ru) Применение эстриола в низкой дозе
DE60331537D1 (de) Kombinationen zur behandlung von multiplem myelom
HRP20110198T1 (hr) Indikacija doziranja progesterona u liječenju traumatske ozljede mozga
MXPA05012155A (es) Metodos y composiciones que utilizan compuestos inmunomoduladores para el tratamiento y manejo de canceres y otras enfermedades.
TW200500355A (en) Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases
IL172082A0 (en) Foamable pharmaceutical compositions and methods for treating a disorder
TNSN07238A1 (en) Method for producing sterile suspensions or lyophilisates of poorly soluble basic peptide complexes. pharmaceutical formulations containing the same, and use thereof as medicaments
MX2010005099A (es) Usos de anticuerpos anti-cd40.
EA201170018A1 (ru) Разагилин для изменения течения болезни паркинсона
TW200806318A (en) Uses of anti-insulin-like growth factor I receptor antibodies
TW200640486A (en) Composition
RU2014127298A (ru) Применения иммуноконъюгатов, мишенью которых является cd138
WO2005046593A3 (fr) Methodes et compositions faisant appel a du thalidomide pour le traitement et pour la gestion de cancers et d'autres maladies
EA200802350A3 (ru) Система доставки лекарств
MXPA05004780A (es) Metodos y composiciones que usan farmacos inhibidores selectivos de citocina para el tratamiento y el manejo de canceres y otros padecimientos.
IS6558A (is) Blandaðar sjúkdómsmeðferðir með æðaskaðandi virkni
WO2024112527A3 (fr) Méthodes de traitement d'une maladie de l'œil liée à la thyroïde
MD3477G2 (ro) Metodă de tratament al hepatitei virale cronice C
MX2012005497A (es) Tivozanib y temsirolimus en combinacion.